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Available online 10 September 2016Dedifferentiation of follicular cells is a central event in resistance to radioactive iodine and patient mortality in
papillary thyroid carcinoma (PTC). We reveal that platelet derived growth factor receptor alpha (PDGFRα) spe-
ciﬁcally drives dedifferentiation in PTC by disrupting the transcriptional activity of thyroid transcription factor-1
(TTF1). PDGFRα activation dephosphorylates TTF1 consequently shifting the localization of this transcription fac-
tor from the nucleus to the cytoplasm. TTF1 is required for follicular cell development and disrupting its function
abrogates thyroglobulin production and sodium iodide transport. PDGFRα also promotes a more invasive and
migratory cell phenotype with a dramatic increase in xenograft tumor formation. In patient tumors we conﬁrm
that nuclear TTF1 expression is inversely proportional to PDGFRα levels. Patients exhibiting PDGFRα at time of
diagnosis are three times more likely to exhibit nodal metastases and are 18 times more likely to recur within
5 years than those patients lacking PDGFRα expression. Moreover, high levels of PDGFRα and low levels of nu-
clear TTF1 predict resistance to radioactive iodine therapy. We demonstrate in SCID xenografts that focused
PDGFRα blockade restores iodide transport and decreases tumor burden by N50%. Focused PDGFRα inhibitors,
combined with radioactive iodine, represent an additional avenue for treating patients with aggressive variants
of PTC.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:




Deaths from papillary thyroid cancer, in excess of 30,000/year
worldwide, are typically preceded by dedifferentiation and resistance
to radioactive iodine treatment (Ferlay et al., 2013). Thyroid develop-
ment and follicular cell function is deﬁned by co-expression of the tran-
scription factors, TTF1 (Nkx2-1) and Pax8, but how these transcription
factors are regulated in thyroid malignant disease is unclear (Antonica
et al., 2012). Follicular cell dedifferentiation,with disrupted thyroglobu-
lin synthesis and NaI symporter (NIS) function, is considered central to
poor outcomes in PTC (Grogan et al., 2013; Lundgren et al., 2006; Xing,
2013; Ke et al., 2013). Patients with aggressive PTC variants often re-
quire multiple doses of radioactive iodine or repeated surgeries to ad-
dress metastatic disease (Dadu and Cabanillas, 2013; Schneider et al.,y, Cross Cancer Institute and the
n, Alberta T6G 1Z2, Canada.
cMullen).
. This is an open access article under2013; Haugen et al., 2016; Randolph et al., 2012). The Cancer Genome
Atlas project deﬁnes PTC as an ERK-driven cancer, but the differentia-
tion status of tumors is complex and the regulation of TTF1 and Pax8 de-
ﬁes individual assessments of BRAF or RAS gene mutations (Cancer
Genome Atlas Research Network, 2014). Treatments including resvera-
trol, rapamycin, and retinoic acid have been examined for their ability to
slow tumor growth or induce differentiation (Liu et al., 2007; Kogai et
al., 2008; Vivaldi et al., 2009; Fernandez et al., 2009; Hou et al., 2010;
Zhang et al., 2011; Oh et al., 2011; Malehmir et al., 2012; Coelho et al.,
2011; Sherman et al., 2013; Yu et al., 2013; Giuliani et al., 2014;
Plantinga et al., 2014). As yet, the benchtop results are conﬂicting and
selective changes in NIS protein expression and iodide uptake in many
of these studies have failed to translate into clinically relevant and dura-
ble responses in radioactive iodine therapy.
The ongoing efforts to identify targeted therapy for dedifferentiated,
metastatic PTC has led to empirically driven clinical trials of different ty-
rosine kinase receptor inhibitors that disrupt MEK, VEGFR, FGFR and
other signaling pathways. These therapies were intended to slowthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(NIS) expression and restore radioactive iodine sensitivity
(Gupta-Abramson et al., 2008; Carr et al., 2010; Bible et al., 2010;
Schneider et al., 2012; Ho et al., 2013; Schlumberger et al., 2015).
The most recent and largest studies, including those with
selumetinib, lenvatinib, and sorafenib, demonstrated varying objec-
tive response rates and exhibited signiﬁcant toxicity (Ferrari et al.,
2015). The mixed outcomes in clinical trials, combined with signiﬁ-
cant side-effect proﬁles and transient effectiveness, has limited the
widespread application of these and other tyrosine kinase receptor
inhibitors in the treatment of advanced disease (Gild et al., 2011;
Klein Hesselink et al., 2015).
To identify factors that drive thyroid dedifferentiation, we assessed
PTC primary tumors, metastatic specimens, primary cell cultures and
cell lines as a function of TTF1 and Pax8 expression. We discovered
that disrupted nuclear TTF1 targeting is characteristic of
dedifferentiated PTC and that PDGFRα is central regulator of thyroid fol-
licular cell dedifferentiation and disease progression in PTC. PDGFRα,
but not its isoform PDGFRβ, speciﬁcally downregulates TTF1 nuclear ex-
pression disrupting iodide transport and thyroglobulin production in
follicular cells as well as potentiating tumor growth in vivo. Clinically,
PDGFRα expression is strongly associated with metastatic disease and
is a marker for disease recurrence aswell as resistance to radioactive io-
dine therapy in PTC. These results provide a strong rationale for the use
of PDGFRα blockade as a therapy to disrupt metastatic PTC tumor
growth aswell as to restore differentiation and sensitivity to radioactive
iodine. This focused approach for patients with aggressive variants of
PTC may provide equal or better outcomes with minimal toxicity com-
pared to current trials using multi-kinase inhibitors.
2. Materials and Methods
Additional details are in the Supplementary Materials and Methods.
2.1. Patient Specimens
Ethics approval was obtained through the University of Alberta
Heath Research Ethics Board ID Pro00018758 (Supplementary Mate-
rials and Methods). A total of 287 patient specimens were selected
with thyroid tumors of which 181 are papillary thyroid carcinomas
(113 without and 68 with lymphatic metastases), 57 are benign follicu-
lar neoplasms and there are 36 normal thyroid tissue specimens and 13
section of metastatic lymph nodes. Clinical data was obtained from a
prospective database maintained at the Cross Cancer Institute tracking
disease from 2002 onwards. Recurrence is deﬁned as an increase in
unstimulated thyroglobulin levels of N0.4 ng/mL, stimulated thyroglob-
ulin levels N2 ng/mL, and/or pathologic evidence of recurrence based on
ultrasound-guided ﬁne needle aspiration biopsy. Radiation dose records
obtained directly from the radioisotope recordsmaintained at the Cross
Cancer Institute.
2.2. Isolation of Primary Thyroid Cancer Cell
Primary thyroid cancer cells were obtained using the Cancer Cell Iso-
lation Kit (Panomics, Inc., Fremont, CA, USA). Tissue was minced to
small pieces under aseptic conditions, digested for 2 h with gentle
mixing at 37 °C and cancer cells were puriﬁed followingmanufacturer's
protocol. Isolated primary cancer cells were cultured in DMEM/F12me-
dium supplemented with 10% FBS and 6H (10mU/mL TSH, 0.01 mg/mL
insulin, 10 nM hydrocortisone, 5 μg/mL transferring, 10 ng/mL somato-
statin and 10 ng/mL glycyl-L-histidyl-L-lysine).
2.3. Short Hairpin (shRNA) Stable Transductions
To selectively and stably knock down the expression of PDGFRα in
the TPC1 and 8305C cell lines we used the HuSH-29 shRNA Vectorsystem (HuSH-29 shRNA Retroviral Vector Systems; OriGene Technolo-
gies, Inc.). Brieﬂy, PTC cells were transduced with the pRS shRNA retro-
virus system (Puro+) followed by selection in puromycin (2.5 μg/mL).
Resistant cells were assessed by western blot to select the sequences
that produced the highest levels of protein expression knock-down.
To stably knock down the PDGFRβ receptor, cells were transduced
with the pGFP-BR-S shRNA retrovirus system (BSD+) followed by se-
lection in blasticidin (500 μg/mL). Resistant cells were again assessed
bywestern blot to select the sequences that produced the highest levels
of protein expression knock-down.
2.4. Gene Transfer
To express human PDGFRα complementary DNA,we used a doxycy-
cline-inducible retrovirus system (Lenti-X Lentiviral Expression Sys-
tems; Clontech Laboratories, Inc., Mountain View, CA, USA). Brieﬂy,
PTC cellswereﬁrst transducedwith the LVX-Tet-On advanced lentivirus
(Neo+) followed by selection in G418 (1.0 mg/mL). Resistant cells
were then transduced with the LVX-Tight-Puro (Puro+) vector or se-
quence-veriﬁed derivatives expressingwild-type human PDGFRα com-
plementary DNA, followed by selection in puromycin (2.5 μg/mL).
Complementary DNA expression was induced by addition of doxycy-
cline (2 μg/mL). To express PDGFRα in the rat cell line FRTL5, the
human cDNA sequence was inserted into pLenti-C-mTagGFP (SgfI/
MluI) following transduction with lentiviral particles cells were sorted
by ﬂow cytometry and the GFP positive population was cultured.
2.5. Wound Healing, Clonogenic, Transwell Invasion and Proliferation
Assays
Cytoselect™ 24-well cell invasion basement membrane assay kit
(Cell Biolabs, San Diego, CA, USA) was used to measure the invasive
properties of the cells. Brieﬂy, the stable TPC1, 8305C and BCPAP cell
lines were seeded at a density of 3 × 105 cells/well and cultured for
48 h. Invasive cells passed through the basement membrane layer, dis-
sociated using detachment buffer and then quantiﬁed by means of
CyQuant GR ﬂuorescent dye. Adherent colony formation assays were
performed as described. Fifty or 100 cells per well were plated in six-
well plates, fed 5% FBS supplemented growth medium and allowed to
form colonies for 20 days. Colonies were stained with 0.5% crystal violet
solution in 25% methanol and counted. For the wound healing assay,
cells were plated in 6 well plates at 80–90% conﬂuence. A wound was
created by manually scratching the cell monolayer with a p1000 or
p200 pipet tip. Cellular debris was removed by washing the monolayer
with PBS and the cells were fed with complete growth medium or
serum-free medium. Images and measurements were acquired at
times 0, 20 and 44 h after wound creation. To document the effect of
PDGFRα or β on proliferation, cultures were incubated in regular or
serum-free-mediumand enumerated daily for 5 dayswith an electronic
cell counter (Coulter Model Zf). The MTS assay (Promega, Madison, WI,
USA)was also performed in 8–16 replicates after 48 and 72 h of growth.
2.6. Mouse Xenograft Models
All experiments were conducted in accordance with the guidelines
of the University of Alberta Animal Care and Use Committee (ACUC)
and the Canadian Council of Animal Care. BCPAP cells (1× 106) express-
ing PDGFRα protein or empty vector (mock) were inoculated subcuta-
neously (1:1 v/v matrigel–PBS) on the left and right ﬂanks
(respectively) of beige SCID mice that received a 0.5 mg slow release
doxycycline pellet, subcutaneously 48 h prior to cell inoculation. The
stable TPC1 and 8305C cells (1 × 106) were inoculated subcutaneously
as described above. Tumor growth was followed and documented and
animals were sacriﬁced once the tumors reached a 1 cm3 size.
Crenolanib was purchased from Selleckchem.
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Ex vivomeasurements of sodium iodide transport in normal thyroid
tissue as well as papillary thyroid carcinomas were performed both as
directmeasurement of radioactive iodide uptake and using a colorimet-
ric iodide assay (Waltz et al., 2010; Weiss et al., 1984). Brieﬂy, 50,000
cells/well were seeded on poly-L-Lys or collagen-coated 96-well plates
and allowed to attach overnight. The rat cell line FRTL5was used as pos-
itive control for all experiments. Cells were washed twice in iodide up-
take buffer (10 mM HEPES/HBSS). After the ﬁnal wash, 80 μL of uptake
buffer was added to all wells and further supplemented with 10 μL of
100 μM NaI solution (uptake wells), 10 μL of 100 μM NaI/450 μM
NaClO4 solution (uptake inhibition wells) or 10 μL of uptake buffer
(background control wells). Plates were incubated for 1 h at 37 °C, 5%
CO2 atmosphere then the solution was completely removed from
wells and plates allowed to dry by blotting on paper towel. Water
(100 μL) was added to all wells followed by 100 μL of 10.5 mM Ammo-
nium Cerium(IV) Sulfate and 100 μL of 24 mM Sodium Arsenite(III) so-
lution and plates were incubated in the dark for 30–90 min at RT,
absorbance readings (420 nm) were taken at 30 min intervals.
2.8. Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded tissue sections of 4 μm thickness
were deparafﬁnized and rehydrated. Evaluation of immunostainingwas
performed without knowledge of the clinical outcome and all speci-
mens had representative sections conﬁrming that N90%of the specimen
consisted of papillary thyroid carcinoma. Sample cores on the tissue
array that were fragmented or incomplete were not scored. As de-
scribed in multiple reports, the cytoplasmic staining of PDGFRα and
PDGFRβ was assessed for each case, in triplicate, as 3+, (strong, dif-
fuse), 2+ (strong, focal), 1+ (weak staining), or 0 (minimal staining)
(Zhang et al., 2012; Gonzalez-Campora et al., 2011; Barreca et al., 2011).
2.9. Statistics
Data were expressed as the mean ± standard error of mean from a
minimum of three independent experiments. Statistical analyses were
performed using the two-tailed Student's t-test for unpaired samples,
with equal variance. The correlations between protein expression and
metastatic status were assessed using Fisher's exact test for tables and
Spearman rank correlation for continuous variables. Statistical tests
are two-tailed with a P value b 0.05 considered to be statistically signif-
icant. Descriptive statistics were used to present the study variables.
Mean and standard deviation were reported for the continuous data
variables, frequency and percentages were reported for categorical var-
iables. Recurrence free survival (RFS) was calculated from the date of
treatment to date of recurrence and the patients who did not recur
were considered censored for the analysis. Kaplan-Meier methods
were used to time to event data, and themedian survival and the corre-
sponding 95% conﬁdence intervalwere reported.When themedian sur-
vivalwas not reached, then the survival probabilitieswere reported. Log
rank tests were used to compare the two survival curves. All statistical
analysis was conducted in SPSS version 15. A P-value b 0.05 was used
for statistical signiﬁcance.
3. Results
3.1. Expression of TTF1, but not Pax8, Is Downregulated by PDGFRα in
Dedifferentiated, Metastatic PTC
Both TTF1 and Pax8 are necessary and sufﬁcient to generate a differ-
entiated thyroid follicular cell that is capable of thyroglobulin produc-
tion and sodium iodide transport (Antonica et al., 2012; Mu et al.,
2012; Zhang et al., 2006). We assessed validated thyroid cancer cell
lines for differentiation as deﬁned by TTF1 and Pax8 and correlatedeach transcription factor with the expression of tyrosine kinase recep-
tors linked to aggressive thyroid malignancy (Gild et al., 2011;
Schweppe et al., 2008). We revealed a strong and speciﬁc association
of PDGFRα with dedifferentiation and loss of TTF1 expression in these
thyroid cancer cell lines (Fig. 1a). Conversely, all the cancer cell lines
expressed Pax8, whereas TTF1 was found in only BCPAP and KTC1
cells in which PDGFRαwas lacking (Fig. 1a). We conﬁrmed the recipro-
cal expression of TTF1 and PDGFRα through qPCR analysis. (Supple-
mentary Fig. 1, a and b). Examples of PDGFRβ and TTF1 co-expression
were identiﬁed, notably in the BCPAP cell line and in primary cultures
of normal human thyroid cells. Pax8 protein expression was not inﬂu-
enced by the presence or absence of either the α- or β-subunits of
PDGFR. Expression levels of other tyrosine kinase receptors linked to
PTC, including FGFR, VEGFR, IGFR, and EGFR, did not reveal variations
in thyroid cell differentiation status as deﬁned by TTF1 or Pax8 expres-
sion (Supplementary Fig. 1c).
To test our hypothesis that expression of PDGFRα disrupts the ex-
pression of TTF1, we generated pooled populations of stable homo-
and heterodimers of PDGFRα and PDGFRβ subunits using veriﬁed PTC
cell lines BCPAP (native PDGFRβ), TPC1 (native PDGFRα and PDGFRβ)
and 8305C (native PDGFRα). All thyroid cancer cell lines express signif-
icant levels of PDGF ligands AA, BB, and DD providing for endogenous
signal activation of the receptors (Zhang et al., 2012). Fig. 1, b–d show
representative Western blots from the cell lines BCPAP, TPC1, and
8305C in which we demonstrate that PDGFRα protein expression re-
duced TTF1 protein levels (BCPAP cells). Conversely, disruption of
PDGFRα expression increases TTF1 protein levels (TPC1 and 8305C
cells). Notably, the presence or forced absence of PDGFRβ (BCPAP and
TPC1 cells respectively) had no impact on the expression of TTF1 in
these cell lines. Strikingly, the forced expression of PDGFRα in primary
cultures derived from benign neoplastic thyroid tissue also markedly
decreased TTF1 expression, even with only small amounts of protein
(Supplementary Fig. 1d). There is also no relationship between the ex-
pression of Pax8 and the level of PDGFRα or PDGFRβ in immortalized
cell lines or patient derived primary cultures (see Fig. 1, b–e).
We then determined TTF1, Pax8 and PDGFRα expression in fresh
tumor isolates from patients since freezing or ﬁxation of thyroid
tumor specimens can induce dramatic variations in nuclear protein iso-
lation (Supplementary Fig. 1e and Supplementary Fig. 2a). Primary tu-
mors lacking clinical evidence of metastases appear to commonly
exhibit TTF1, but lack PDGFRα (Supplementary Fig. 1e). By contrast, iso-
lates from metastatic specimens expressed high levels of PDGFRα but
minimal TTF1 in almost all cases (P = 0.005) (Supplementary Fig. 1e).
These results are consistent with previous studies indicating that
PDGFRα gene transcript levels are 30–40 times lower than PDGFRβ in
normal thyroid tissue (GTEx Consortium, 2013). Moreover, our own
mRNA screen comparing patientmatched primary tumors andmetasta-
tic disease specimens revealed a dramatic upregulation of PDGFRα at
levels much higher than other tyrosine kinase receptors (Fig. 1e). Pax8
protein expression does not appear to vary based on the presence of
metastatic disease. Lastly, we reveal using ﬂow cytometry that primary
thyroid carcinomas lacking metastases exhibited low levels of PDGFRα
but that metastatic specimens sectioned from lymph nodes revealed
much higher levels of PDGFRα on the cell surface (P b 0.0001) (Fig.
1f). Overall, PDGFRα is a prominent feature of metastatic disease and
it is inversely related to TTF1 expression in both cell lines and clinical
specimens.
3.2. PDGFRα Expression Creates a Dedifferentiated Phenotype by Disrupting
Nuclear Localization of TTF1
TTF1 protein levels are clearly diminished in the presence of
PDGFRα. However, TTF1 mRNA levels decreased only marginally
when assessed with, and without, exogenous ligand to maximize
PDGFRα activation and under varying growth conditions (Supplemen-
tary Fig. 2b). The same is true for Pax8 mRNA levels (Supplementary
Fig. 1. PDGFRα expression induces dedifferentiation in thyroid cancer cells by disrupting nuclear TTF1 protein expression. (a) Western blot of thyroid cancer cell lines KTC1, BHT101,
BCPAP, TPC1, 8305C, and SW579 demonstrate an inverse relationship between PDGFRα and TTF1 expression. NT: normal thyroid primary culture control. (b) Western blot of BCPAP
cells with inducible expression of PDGFRα under a doxycycline promoter disrupts TTF1 expression. BCPAP cells transduced with empty vector as a control (mock). (c) Western blot
demonstrating that expression, or selective knockdown, of PDGFRα in TPC1 cells disrupts or restores, TTF1 expression. This effect is not altered by the presence of PDGFRβ. Cells
transduced with non-effective shRNA cassette as control (mock). (d) Selective knockdown of PDGFRα in dedifferentiated thyroid cancer cell line 8305C restores TTF1 expression. (e)
mRNA screen comparing patient matched primary tumors and metastatic disease. (f) Quantitative analysis using ﬂow cytometry of freshly isolated primary tumors comparing
PDGFRα positive cells in primary tumors lacking metastases (n = 4) with proven metastatic disease (n = 6), results are means ± SEM.
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function, we examined cytosolic and nuclear cell fractions for the abun-
dance of each transcription factor (Antonica et al., 2012; Zannini et al.,
1996). Pax8was found in both the cytoplasm and nucleus in the thyroid
cancer cell lines whereas TTF1, when expressed, was almost exclusively
localized to the nuclear cellular fractions (Fig. 2a). Given the similar
mRNA levels of TTF1with andwithout PDGFRα expression,we then ex-
amined the phosphorylation status of TTF1 in BCPAP cells. We hypoth-
esized that nuclear targeting of TTF1 may be altered by variations in
phosphorylation since previous studies indicated that TTF1 transcrip-
tional activity varied with phosphorylation but not DNA-binding activi-
ty (Zannini et al., 1996; Missero et al., 2000). Using 2D electrophoresis
we consistently observed two populations of TTF1 in the absence of
PDGFRα (Fig. 2b). With expression of PDGFRα we observed N80% re-
duction of the second,more acidic population consistentwith decreased
TTF1 phosphorylation. The PDGFRα-induced dephosphorylation of
TTF1 was possibly driving decreased nuclear targeting and functional
impairment of TTF1 so we quantiﬁed the nuclear:cytoplasmic ratios of
TTF1 and Pax8 in the BCPAP cell line using confocal microscopy. Therewas a signiﬁcant cytoplasmic shift in TTF1 protein localization with
PDGFRα expression (Fig. 2, c and d). The expression of PDGFRα did
not signiﬁcantly impact the localization or relative expression levels
of Pax8 in the BCPAP cell line (Fig. 2, e and f). We also conﬁrmed that
there was a shift in TTF1 from the nucleus to the cytoplasm with the
expression of PDGFRα in primary cultures of clinical specimens of
metastatic PTC (Fig. 2, g and h). Lastly, we were able to increase nu-
clear targeting of TTF1 in both mock and PDGFRα + BCPAP cells
using phosphatase inhibitors, as shown in Supplementary Fig. 2d.
Our results are consistent with recent work outlining the key role
of nuclear TTF1 in folliculogenesis (Silberschmidt et al., 2011) and
we demonstrate the role of phosphorylation in subcellular targeting
of TTF1.
3.3. PDGFRαDrives Profound Changes in Follicular Cell Morphology, Colony
Formation, Migration and Invasive Potential
We next assessed surrogate markers of tumorigenic potential
including proliferation, colony formation, migration and invasive
Fig. 2. PDGFRα expression decreases TTF1, but not Pax8, expression and nuclear localization. (a) Western blot of cytoplasmic and nuclear protein extracts of the papillary thyroid
carcinoma cell lines examined in this study. (b) 2D electrophoresis pattern of TTF1 as measured in BCPAP mock and PDGFRα expressing cells. The spot intensity for the two most
prominent protein spots (relative to the single spot to the far left in PDGFRα expressing cells) is shown as mean ± SEM of four independent runs. (c) Confocal microscopy reveals
cytoplasmic shift of TTF1 localization through comparison of BCPAP mock and BCPAP transduced with inducible PDGFRα. Scale bar 25 μm. (d) Confocal microscopy was used to
quantify the change in the nuclear:cytoplasmic ratio of TTF1 localization through comparison of BCPAP mock and BCPAP transduced with inducible PDGFRα. (e) Expression of PDGFRα
protein does not have a signiﬁcant impact on Pax8 localization as shown by confocal microscopy. Scale bar 25 μm. (f) Confocal microscopy reveals no change in the nuclear:cytoplasmic
ratio of Pax8 comparing BCPAP mock and BCPAP PDGFRα cells. (g) PTC primary cultures with and without metastases demonstrate the cytoplasmic localization of TTF1 with PDGFRα
expression and this is quantiﬁed in (h). Scale bar 25 μm. Data are presented as mean ± SEM, n = 10–25 individual cells.
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different ways to selectively express, or repress, PDGFRα. Expression of
PDGFRα in the PTC cell line produced dramatic changes in themorphol-
ogy of the cells grown in two-dimensional culture. In particular, we saw
a cellular morphology consistent with dendritic-projections and in-
creased cell surface area as shown for BCPAP (Fig. 3a). These changes
in cellular morphology were quantiﬁed by cell area (Supplementary
Fig. 3a). Expression of PDGFRα increased colony formation nearly 6-
fold in BCPAP cells, while colony formation in 8305C cells was inhibited
N5-fold with PDGFRα knock-down (Fig. 3b and Supplementary Fig. 3b).
Wound closure rates for BCPAP and 8305C cells were also signiﬁcantly
faster in cells incubated in nutrient rich environment (10% FBS) when
PDGFRα was expressed (Fig. 3c). The invasion assay generallyconﬁrmed our other functional assessments where selective blockade
or disruption of PDGFRα expression generally leads to a less invasive
phenotype (Fig. 3d).We also assessed the ability of thyroid cancer tissue
isolates, with and without PDGFRα, to generate thyroid spheres as an-
other surrogate of tumorigenic potential. In thyroid follicular cells lack-
ing PDGFRα, we saw small thyrospheres that plateaued in growth after
approximately 14 days. However, primary thyroid cultures transfected
with PDGFRα demonstrated a growth pattern consistent with
invadopodia-like structures as was seen with 3D-culture (Fig. 3e).
There were minimal differences in cell growth rates when we altered
the expression of the alpha subunit in PTC cell lines (Fig. 3f). The results
for TPC1 cells were qualitatively similar to that described above, with or
without PDGFRα, as shown in Supplementary Fig. 3, c–e. The PDGFRα
Fig. 3. PDGFRα expression induces a dramatic phenotypic change in PTC cell lines. (a) Two-dimensional culture micrographs demonstrate the signiﬁcant change in cellular morphology
with insertion of the PDGFRα gene into BCPAP cells. Scale bar 50 μm. (b) Colony formation in the cell lines with different PDGFR subunit compositions. n= 6. (c) Thewound healing assay
with closure of thewound examined at 44 h in three independent experiments. Results were qualitatively and quantitatively similarwith (shown) andwithoutmitomycin C to inhibit cell
division. n = 8. (d) Invasive potential was studied using the basement membrane cell invasion assay kit. After 48 h incubation, invasive cells were dissociated, lysed, and quantiﬁed by
CyQuant GR Dye. RFU: relative ﬂuorescence units. n = 8. (e) 3D culture assessment of varying growth patterns between PDGFRα-positive and negative thyroid primary cultures. Scale
bars 200 μm, inset 50 μm. (f) Cellular proliferation as quantiﬁed by cell count in the PTC cell lines did not reveal signiﬁcant differences in proliferative potential with the insertion of
the PDGFRα subunit. n = 8. Results in B, C, D and F are means ± SEM.
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expressed alone or with PDGFRβ (Supplementary Fig. 3f).
3.4. PDGFRα Expression Decreases Thyroglobulin Production and Sodium
Iodide Transport in Tumorigenic and Non-tumorigenic Thyroid Follicular
Cells
Functional differentiation in thyroid cancer cell lines is typically
measured by thyroglobulin production and iodide transport. There
was minimum or no detectable mRNA for the NIS or thyroglobulin
in the thyroid cancer cell lines BHT101, 8305C, TPC1, SW579, con-
sistent with previous reports (Pilli et al., 2009). However, native
BCPAP cells exhibit both TTF1 and Pax8 and there was a correspond-
ingly modest mRNA expression for thyroglobulin and NIS (Fig. 4, a
and b). These results are consistent Pax8 and TTF1 being necessary
for differentiated thyroid cell function (Antonica et al., 2012).Expressing PDGFRα in BCPAP cells caused a dramatic decrease in
mRNA levels for both thyroglobulin and NIS consistent with loss of
TTF1 functionality (Fig. 4, a and b). Note that PDGFRα-driven
changes in differentiation were not qualitatively altered by the
growth conditions or different growth factors as documented by
thyroglobulin levels (Supplementary Fig. 4). Conversely, when we
knocked down PDGFRα (restoring TTF1 expression) we were able
to restore thyroglobulin (Fig. 4c) and NIS (Fig. 4d) mRNA levels in
8305C cells. As expected, corresponding changes in iodide transport
were seen with decreased NaI transport in PDGFRα + BCPAP cells
(Fig. 4e), whereas PDGFRα knockdown facilitated limited iodide
transport in 8305C cells (Fig. 4f). We show that the PDGFRα-medi-
ated disruption of NaI transport is dramatic and virtually complete
even in non-tumorigenic cell lines such as in rat FRTL5 cells,
which represent the model system by which NaI transport has
been deﬁned (Fig. 4g).
Fig. 4. Follicular cell function is disrupted by PDGFRα protein expression. The effects of PDGFRα expression on the relativemRNA levels in BCPAP cells are shown for (a) thyroglobulin and
(b) sodium iodide symporter (NIS). (c) and (d) show relative thyroglobulin and NIS mRNA expression, respectively, in 8305C cells. (e) Dedifferentiation and the consequential effect on
sodium iodide transport in BCPAP cells with and without PDGFRα expression. (f) Dedifferentiation and the consequential effect on sodium iodide transport in 8305C cells (mock and
shPDGFRα). Results are means ± SEM, n = 6 of three independent experiments. (g) Effect on sodium iodide transport in FRTL5 cells expressing PDGFRα. Results are means ± SEM,
n = 8 of 5 independent experiments. Gene expression was normalized to GAPDH expression levels in all experiments.
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The tumorigenic potential of PDGFRα was assessed by implanting
BCPAP cells, with and without PDGFRα expression, into SCID mice.
PDGFRα expression was associated with a nearly 10-fold increase in
tumor growth (Fig. 5a). The same pattern was seen with 8305C and
TPC1 cells where the selective disruption of PDGFRα expression lead
to a dramatic decrease in tumorigenic potential but blockade of PDGFRβ
did not decrease tumorigenic potential (Fig. 5, b and c). Representative
H&E sections for the BCPAP mock cell line tumors and those with
PDGFRα cell line are shown in Supplementary Fig. 5a. As predicted the
expression of TTF1, but not Pax8, in the tumors is decreased by PDGFRα
as shown byWestern blot (Supplementary Fig. 5b). Immunohistochem-
istry conﬁrms the inverse relationship between PDGFRα and TTF1 pro-
tein expression in BCPAP mouse xenografts (Fig. 5d). We also
demonstrated that iodide transport in BCPAP xenograft cells was signif-
icantly decreased when the PDGFRα subunit was expressed in thexenografted cells (Fig. 5e). Moreover, as amodel for dedifferentiated tu-
mors, we used native 8305C cells to demonstrate that knocking down
PDGFRα or blocking PDGFRα activation with crenolanib signiﬁcantly
decreased tumor burden (Fig. 5f).
3.6. PDGFRα Expression Is Associated With Cytoplasmic TTF1 Expression
and Nodal Metastases
Resistance to radioactive iodine therapy is a central feature of dis-
ease recurrence and poor outcomes in thyroid cancer. Assessments of
individual freshly isolated PTC specimens revealed that PDGFRα expres-
sion by Western blot in metastatic disease was associated with de-
creased NIS levels and loss of sodium iodide transport (Fig. 6a). This
relationship was further explored with tissue arrays comprised of nor-
mal thyroid tissue, benign neoplasms, PTC primary tumors with and
without lymph node metastases with clinical follow-up data for an av-
erage of 7.9 years (range 2.4 years to 11.1 years). Patient age, sex,
Fig. 5. PDGFRα drives tumorigenesis in vivo. (a) BCPAP-derived tumors,with andwithout PDGFRα in SCIDmice. Fivemice per groupwere inoculatedwith BCPAPmock or BCPAP PDGFRα
derived cell lines inMatrigel, results aremeans±SEM. (b) Knockdownof the alpha or beta subunits of PDGFR in TPC1 reveal that blockade of the alpha subunit produces themost dramatic
decrease in tumor growth. The average tumor volume is shown until sacriﬁce at day 20. Results are mean ± SEM. (c) 8305C-derived tumors in SCID mice. Five mice per group were
inoculated with 8305C mock or shPDGFRα derived cell lines in Matrigel. Results are means ± SEM. (d) Reciprocal relationship between the pattern of PDGFRα and TTF1 staining in
tumor xenografts obtained by injecting BCPAP mock and BCPAP PDGFRα cells into SCID mice. Scale bars 400 μm and 50 μm (inset). (e) Effect on sodium iodide transport of crenolanib
treatment (0.8 mg/mL) in the SCID xenograft of BCPAP expressing PDGFRα and 8305C cells. Results are means ± SEM, n = 3 independent ex-vivo isolations (f) 8305C-derived tumors
in SCID mice. Five mice per group. Animals were treated daily with vehicle (peanut oil) or crenolanib (8 mg/kg), administered daily at 0.8 mg/mL starting 24 h post inoculation until
termination (day 19). Results are means ± SEM, n = 3 vehicle, n = 5 crenolanib.
93A. Lopez-Campistrous et al. / EBioMedicine 12 (2016) 86–97tumor size and lymphnode yields are outlined for each group in Supple-
mentary Table 1.
The substantial cross-reactivity of commercially available PDGFRα
and β antibodies required an antibody screening process using a series
of T47D breast cancer cell lines that we generated to selectively express
human PDGFRα and PDGFRβ (see Supplementary Fig. 5c). PDGFRα im-
munohistochemical staining in patient tumor samples was linked
strongly to a shift in TTF1 staining from the nucleus to cytoplasm and
this was especially pronounced in metastatic disease. Node negative
PTC specimens exhibited greater nuclear than cytoplasmic staining,
whereas we consistently observed strong and speciﬁc nuclear staining
for TTF1 in histologically normal or benign follicular disease (Fig. 6b,
top panel). The alpha subunit of PDGFRwas found atmuchhigher levels
in PTC specimens with nodal metastases compared to primary tumors
lacking evidence of metastases (Fig. 6b, center panel). It should be
noted that Pax8 exhibits primarily a nuclear localization in all samples
(Fig. 6b, bottom panel). The scoring summary for the immunohisto-
chemistry is shown in Supplementary Table 2 and the quantiﬁcationof the mean nuclear staining intensities of TTF1 and PDGFRα as a func-
tion of tissue type is shown in Fig. 6c.
3.7. PDGFRα and CYTOPLASMIC TTF1 Levels Are Prognostic Markers of Re-
currence, Lymph Node Involvement and Radioactive Iodine Resistance in
PTC
PDGFRα positive tumor specimens at the time of diagnosis were
more than three times more likely to exhibit nodal metastases
(P b 0.0001), and were larger (P = 0.03) than tumors with minimal
PDGFRα staining. TTF1 exhibited the inverse relationship with low nu-
clear staining levels associated with larger tumors (P = 0.0001) and
nodal metastases (P = 0.0008). Radiation data reveal that patients
exhibiting PDGFRα were given signiﬁcantly higher therapeutic doses
of radioactive iodine (P = 0.005) compared to patients with low
TTF1 levels (P = 0.007) (Fig. 7a). We also examined a cohort of
patients initially lacking ultrasound or biochemical (thyroglobulin
(Tg) b 0.4 ng/mL) evidence of nodal metastases that were followed
Fig. 6. High PDGFRα expression in humanmetastatic PTC is associated with decreased sodium iodide symporter transport function and follicular cell differentiation. (a) Primary thyroid
cultures thatwere prepared from freshly isolated cells frompatients show the inverse relation between iodide transport andPGFRα expression inprimary thyroid cancer versusmetastatic
PTC. Inset: Western blots of corresponding primary thyroid cultures revealing predicted changes in sodium iodide symporter (NIS) protein levels due to expression of PDGFRα, rat FRTL5
thyroid cells are shown for comparison. Results aremeans±SEM,n=6. (b) Representative immunohistochemical staining for TTF1 (top), PDGFRα (middle) and Pax8 (bottom) innormal
thyroid, benign neoplasms and primary tumors with, and without, nodal metastases. Scale bars 50 μm. (c) Mean staining intensities for TTF1 and PDGFRα proteins in arrayed thyroid
clinical specimens including normal tissue, benign neoplasms, primary PTC and metastatic PTC. Results are means ± standard errors. N as described in Supplementary Table 1.
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disease as deﬁned by positive ultrasound scans, an unstimulated Tg
level of N0.4 ng/mL or a stimulated Tg of N2.0 ng/mL. PDGFRα-positive
tumors were N18 times more likely to recur (95% CI: 4.2–82.4,
P b 0.0001) than those cases lacking PDGFRα even when matched for
the dose of radiation supplied to the patients (P = 0.28) (Fig. 7b).
Low levels of TTF1 nuclear expression correlated strongly with re-
current disease (HR = 5.3 95% CI: 1.7–16.3, P = 0.004) even when
they were subjected to higher doses of radiation (P = 0.003) (Fig. 7c).
These results did not vary for patients above or below 45 years of age
as shown in Supplementary Fig. 6, a and b. Given the inverse relation-
ship between TTF1 and PDGFRα, the overall expression of TTF1 and
the nuclear/cytoplasmic ratio may be very useful surrogates to identify
both increased metastatic potential and resistance to radioactive iodine
and a potential for treatment with PDGFRα blockade. In our current
model, it appears that targeted blockade of PDGFRαmay be an essential
to restore differentiation in the treatment of aggressive PTC variants
with metastases resistant to radioactive iodine (Fig. 8).
4. Discussion
Wedemonstrated that PDGFRα, but not PDGFRβ, can induce thyroid
follicular cell dedifferentiation by excluding TTF1 from the nucleus.
PDGFRα promotes an aggressive disease phenotype in PTC via two
mechanisms. First, PDGFRα disruption of TTF1 transcriptional activity
abrogates NIS function and iodide transport. Second, this receptor also
drives an increase in the invasive potential of thyroid follicular cell
lines and promotes tumor formation in xenografts. Patients exhibitingPDGFRαwere three timesmore likely to present with nodal metastases
and they received nearly twice the dose of radioactive iodine compared
to patients lacking expression of PDGFRα in their tumors. Patients lack-
ing clinical evidence of metastatic disease at diagnosis, but with
PDGFRα-positive tumors, were muchmore likely to have recurrent dis-
ease than patients lacking PDGFRα.We ensured that thiswas truewhen
patients received similar doses of radiation and also when matched for
patient age. Differences in survival were not observed in this cohort.
However, previous studies examining outcomes over decades showed
that recurrent PTC is predictive of increased mortality (Grogan et al.,
2013). It is also well-documented that increased use of radioactive io-
dine and repeated surgeries increasemorbidity including lifelong hypo-
parathyroidism and sialoadenitis (Fard-Esfahani et al., 2014). Since
PDGFRα predicts resistance to radioactive iodine and increased risk
for nodal metastases, this could be used to inform decisions regarding
prophylactic node surgery in PTC. It can also deﬁne those patients at
low risk of recurrence who may not beneﬁt from the use of radioactive
iodine. Lastly, inhibition of PDGFRα in vitro and in vivo generated a dif-
ferentiated disease phenotype with slower tumor growth and greater
avidity for radioactive iodine uptake.
Dedifferentiation through loss of TTF1 transcriptional activity is cen-
tral to the mechanism of PDGFRα action in PTC. We demonstrated that
PDGFRα-induced changes in TTF1 phosphorylation transformed benign
thyroid follicular cells, as well as immortalized thyroid cancer cell lines
of varying derivations, into more invasive phenotypes lacking expres-
sion of thyroglobulin and sodium iodide transport. Our cell lines exhibit
BRAF V600E (BCPAP) or RET/PTC (TPC1)mutations, or represent a poor-
ly differentiated form (p53mutation) of PTC (8305C). Thus, the inverse
Fig. 7. Radiation dose distribution as a function of PDGFRα and TTF1 staining. (a) Scatter
plot of radiation doses for patients stratiﬁed by high or low levels of PDGFRα and TTF1
on immunohistochemical stains. Results are unpaired t-tests for 152 patients. (b)
Kaplan-Meier plots of disease recurrence as a function of time based on PDGFRα
immunohistochemical staining. (c) Kaplan-Meier plots of disease recurrence as a
function of time based on TTF1 immunohistochemical staining.
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a single cell line variant or activation of a single pathway. Regulation of
TTF1 is not well understood in thyroid neoplastic disease, but its role in
deﬁning patient outcomes and response to therapy has been studied ex-
tensively in acute lymphoblastic leukemia and lung cancer (Yamaguchi
et al., 2013). Previous studies revealed a complex picture of TTF1 regu-
lation that could not be accounted by individual assessments of Ras,
ERK, PI3K, protein kinase A, and cyclic AMP contributions to TTF1 tran-
scriptional activity (Missero et al., 2000; Silberschmidt et al., 2011; Yan
and Whitsett, 1997; Feliciello et al., 2000). Thyroid-speciﬁc expression
of thyroglobulin and other genes relies on the phosphorylation of
three to seven serines on TTF1 (Zannini et al., 1996). However,
these same investigators found that DNA-binding of TTF1 isphosphorylation-independent (Zannini et al., 1996). In the current
work it is clear that subcellular nuclear targeting of TTF1 is the gateway
to thyroid follicular cell function. The dephosphorylation of TTF1moves
it from the nucleus and into the cytoplasm ultimately disrupting TTF1-
mediated transcription. This accounts for the results of Zannini et al.
(1996) and explains why phosphorylation inﬂuences transcriptional
activity without altering DNA binding activity. We also observe that
overall levels of TTF1 protein diminish with dephosphorylation and cy-
toplasmic localization, consistent with that shown for thyroid (Missero
et al., 2000) and lung cell lines (Kumar et al., 2000). We further show
that TTF1 in clinical specimens is increasingly localized to the cytoplasm
as expected withmore aggressive disease. Zhang et al., 2012 previously
outline that phospho-PDGFRα activates the Akt and ERKpathwayswith
both pathways contributing to the invasive potential of thyroid cancer
cell lines. We continue to explore how altered TTF1 function and in-
creased downstream signaling of PDGFRα pathways (i.e. Akt, ERK,
STAT3) work together to promote aggressive variants of PTC.
A central challenge to advancing therapy for progressive PTC is to
improve the responses to tyrosine kinase receptor therapy, while mini-
mizing toxicity. So far, the response rates are typically 20% (range 0–
45%) and there was substantial toxicity documented from trials using
tyrosine kinase receptor inhibitors such as sorafenib, selumetinib, and
lenvatinib (Gild et al., 2011; Klein Hesselink et al., 2015). The mecha-
nism of action of these drugs is complex, possibly reﬂecting an impact
on PDGFRα (in the mM range) as well as other downstream pathways
including ERK that may inﬂuence differentiation. Targeted therapies
such as sorafenib clearly inhibit multiple signaling pathways in thyroid
carcinomaand can induce cell cycle arrest and initiation of apoptosis. No
previous study has documented changes in TTF1 or Pax8 expression or
transcription. Here we establish a link between the tyrosine kinase re-
ceptor PDGFRα, TTF1 expression, dedifferentiation, and radioactive io-
dine transport in PTC. We are exploring if focused disruption of
PDGFRα by small molecules or monoclonal antibody therapy could be
sufﬁcient to induce clinically relevant responses in tumor growth, dif-
ferentiation, and iodide transport. While it is clear that BRAF and RAS
mutations may have a role in tumorigenesis, the subset of thyroid can-
cers most likely to generate metastases and poor outcomes are
dedifferentiated tumors. We believe that targeted therapy of PDGFRα
may decrease tumor progression while also inducing differentiation
without the side-effects that limit the use of multi-kinase agents to
only patients with the most advanced disease.
We demonstrate in cell lines, SCID xenografts and human tumor
specimens that PDGFRα promotes dedifferentiation in PTC by decreas-
ing TTF1 expression in the nucleus, which decreases iodide transport
and thyroglobulin production in thyroid follicular cells. Our study pro-
vides a proof of principle that selectively blocking PDGFRα signaling
could signiﬁcantly improve radioactive iodine treatment and decrease
metastases in PTC. This selective therapy could improve outcomes
while minimizing side effects compared to drugs that blockmultiple ty-
rosine kinase receptors.
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